InvestorsHub Logo
Followers 87
Posts 6625
Boards Moderated 0
Alias Born 06/07/2016

Re: abeta post# 613484

Tuesday, 07/25/2023 7:30:50 AM

Tuesday, July 25, 2023 7:30:50 AM

Post# of 701723
It is interesting and promising showing the future of trials, also of interest, of a total of 47 patients in the phase 2b trial the most common AEs patients experienced during the treatment period and follow-up included 20 patients with seizure (42.6%).

https://www.targetedonc.com/view/bizaxofusp-demonstrates-encouraging-survival-in-recurrent-glioblastoma
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News